ACB Stock Chart & Stats
$2.67
$0.07(2.62%)
At close: 4:00 PM EDT
$2.67
$0.07(2.62%)
Day’s Range― - ―
52-Week Range$2.56 - $6.67
Previous Close$2.73
Volume1.41M
Average Volume (3M)1.17M
Market Cap
$254.78M
Enterprise Value$117.20
Total Cash (Recent Filing)$149.12M
Total Debt (Recent Filing)$22.68M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Nov 11, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding64,861,820
10 Day Avg. Volume1,118,228
30 Day Avg. Volume1,168,832
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.81
P/FCF Ratio-7.20
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.10Price Target Upside53.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$206.02M
Bulls Say, Bears Say
Bulls Say
International Medical GrowthInternational growth and greater geographic diversification reduce reliance on Canada and support Aurora’s position in regulated medical markets. Continued expansion in Germany and other countries could provide a durable foundation for revenue growth.
High Adjusted Gross MarginA 58% adjusted gross margin indicates that Aurora’s international product mix and operating model can generate attractive unit economics. Sustained margin performance would improve the company’s ability to absorb regulatory and pricing pressure.
Debt-Free Balance SheetSubstantial liquidity and no debt reduce refinancing risk and provide flexibility to fund operations, capacity expansion and selective acquisitions. This financial resilience is particularly valuable while the company works toward sustained profitability.
Bears Say
Persistent Revenue And Profitability WeaknessDeclining trailing revenue and continued losses show that Aurora has not yet established durable earnings power. Although gross margin has improved, volatile results and negative profitability increase uncertainty around the sustainability of its turnaround.
Negative Free Cash FlowOngoing cash burn can limit Aurora’s ability to reinvest in growth without drawing down liquidity, even with a strong balance sheet. Persistent negative free cash flow would increase execution risk and weaken financial flexibility over time.
Canadian Medical Reimbursement PressureThe reimbursement reduction is a structural regulatory headwind for Canadian medical revenue and gross profit. Lower reimbursement rates may pressure demand, pricing and margins, forcing Aurora to rely more heavily on international growth and cost discipline.
Aurora Cannabis News
ACB FAQ
What was Aurora Cannabis (US)’s price range in the past 12 months?
Aurora Cannabis (US) lowest stock price was $2.56 and its highest was $6.67 in the past 12 months.
What is Aurora Cannabis (US)’s market cap?
Aurora Cannabis (US)’s market cap is $254.78M.
When is Aurora Cannabis (US)’s upcoming earnings report date?
Aurora Cannabis (US)’s upcoming earnings report date is Nov 11, 2026 which is in 80 days.
How were Aurora Cannabis (US)’s earnings last quarter?
Aurora Cannabis (US) released its earnings results on Aug 05, 2026. The company reported -$0.051 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.082.
Is Aurora Cannabis (US) overvalued?
According to Wall Street analysts Aurora Cannabis (US)’s price is currently Undervalued.
Does Aurora Cannabis (US) pay dividends?
Aurora Cannabis (US) does not currently pay dividends.
What is Aurora Cannabis (US)’s EPS estimate?
Aurora Cannabis (US)’s EPS estimate is -0.05.
How many shares outstanding does Aurora Cannabis (US) have?
Aurora Cannabis (US) has 64,861,820 shares outstanding.
What happened to Aurora Cannabis (US)’s price movement after its last earnings report?
Aurora Cannabis (US) reported an EPS of -$0.051 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went up 3.559%.
Which hedge fund is a major shareholder of Aurora Cannabis (US)?
Currently, no hedge funds are holding shares in ACB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurora Cannabis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.10 (53.64% Upside)
$4.10 (53.64% Upside)
Blogger Sentiment
Bullish
ACB Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $48.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.73%
Trailing 12-Months
Company Description
Aurora Cannabis (US)
Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from facility engineering and design to genetic research, production, and the development of new products, all supported by extensive wholesale and retail networks. For medical users, Aurora offers diverse strains of dried cannabis, oils, capsules, and topical kits. Additionally, it markets a range of accessories, including vaporizers, consumable parts, herb mills (specifically for CanniMed products), grinders, and lockable vaporizer containers. The company is committed to advancing medical cannabis, with ongoing development across oral, topical, edible, and inhalable product categories. Aurora also provides key services such as patient counseling, design and construction assistance, and comprehensive analytical product testing for cannabis, alongside operating CanvasRX, a network dedicated to cannabis counseling and outreach. Its expansive brand family includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The corporate headquarters are located in Edmonton, Canada.
ACB Company Deck
ACB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: material short-term financial headwinds (notably a large year-over-year decline in adjusted EBITDA, lower adjusted net income, and negative free cash flow) driven largely by an external 30% reimbursement cut in Canadian medical. Offsetting these negatives are clear strategic strengths—17% international revenue growth to $43M, a 58% adjusted gross margin, strong cash position with no debt, an accretive EU GMP acquisition (Safari), genetics-driven production advantages (up to 40% yield improvement), and market leadership in several regulated international markets. Management frames FY2027 as a transitionary year with expected sequential improvement in Q2 and reiterated long-term targets (sustained double-digit growth and superior margins). Given the mix of significant near-term financial declines and pronounced strategic/operational positives, the overall tone is balanced.View all ACB earnings summariesACB Stock 12 Month Forecast
Average Price Target
$4.10
▲(53.64% Upside)
Technical Analysis
Ownership Overview
0.59% Insiders
0.07% Mutual Funds
1.21% Other Institutional Investors
94.60% Public Companies and
Individual Investors